To access the call please dial 800-239-9838 (domestic) or 323-794-2551 (international) and refer to conference ID 1395205. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In
Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit https://sperotherapeutics.com.
Spero Therapeutics Contacts:
Phone: +1 (617) 798-4039
Phone: +1 (617) 430-7577
Media Contact: firstname.lastname@example.org
Source: Spero Therapeutics, Inc.